The major cause of death around the world is cardiovascular disease, while cancer ranks
second. Lung cancer stands out as a major cause of concern because it accounts for 12% of …

Adagrasib is a recently US FDA-approved novel KRASG12C targeted therapy with clinical
efficacy in patients with advanced, pretreated KRASG12C-mutated non-small-cell lung …

Introduction The current standard of care of locally advanced non-small cell lung cancer (LA-
NSCLC) is concurrent chemoradiation, followed by consolidation durvalumab. However …

Objectives This study aimed to evaluate the prognostic and potential therapeutic value of
expanded molecular testing of resected early-stage lung ACA. Methods We analyzed 324 …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival. To
explore an uncharted function of K-Ras proto-oncogene, K-Ras was activated in …

MLK4, a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family, has
been implicated in cancer progression. However, its role in lung adenocarcinoma has not …

Brain metastases are a significant source of morbidity and mortality in patients with non-
small cell lung cancer. Historically, surgery and radiation therapy have been essential to …

Background A primary pulmonary invasive mucinous adenocarcinoma (IMA) is a rare
subtype of invasive adenocarcinoma of the lung. The prognosis of advanced IMA depending …

Introduction: Driver molecular aberrations, such as EGFR and BRAF mutations, ALK and
ROS1 rearrangements, play an important role in the oncogenesis of non-small-cell lung …

KRAS mutations are frequently detected in non-small cell lung cancers (NSCLCs). Although
covalent KRAS G12C inhibitors have been developed to treat KRAS G12C-mutant cancers …